Skip to main content
S&P 5007,656.98+0.86%DOW52,573.29+0.98%NASDAQ26,333.03+0.96%BTC$77,267.00+0.58%ETH$2,510.86+2.27%GOLD$4,390.00-0.39%OIL$99.99-2.43%
Smart Investors Daily
CL

AMEX · CLDI

Calidi Biotherapeutics, Inc.

Healthcare · Biotechnology

$1.24

Down-$0.07 (-5.34%)

Updated Sep 12, 2026, 8:14 AM

SID Score

5.6/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
10.39M
P/E ratio
-0.28
Dividend yield
0.00%
52-week range
$0.10 – $1.93
Volume
70.66K
Avg. volume
161.89K

Price performance

CLDI price history

1M range · 20 trading sessions · Daily adjusted prices

CLDI closed at $1.24 after 20 trading sessions, down 22.01% for the selected period.

Last close
$1.24
Period change
-22.01%
Period low
$1.24
Period high
$1.59
Daily close
View OHLC price history
CLDI OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 11, 2026$1.24$1.28$1.22$1.2470.66K
Sep 10, 2026$1.31$1.34$1.30$1.3132.47K
Sep 9, 2026$1.33$1.37$1.3007$1.3646.04K
Sep 8, 2026$1.38$1.3997$1.2501$1.3531.39K
Sep 4, 2026$1.38$1.40$1.35$1.38525.75K
Sep 3, 2026$1.33$1.38$1.32$1.3523.9K
Sep 2, 2026$1.332$1.41$1.33$1.3430.63K
Sep 1, 2026$1.33$1.36$1.2801$1.3350.37K
Aug 31, 2026$1.32$1.38$1.31$1.3436.38K
Aug 28, 2026$1.32$1.37$1.28$1.3252.01K
Aug 27, 2026$1.33$1.42$1.26$1.30129.62K
Aug 26, 2026$1.31$1.37$1.31$1.3539K
Aug 25, 2026$1.35$1.405$1.31$1.3148.64K
Aug 24, 2026$1.34$1.38$1.26$1.3862.41K
Aug 21, 2026$1.35$1.41$1.31$1.3458.9K
Aug 20, 2026$1.35$1.39$1.27$1.3479.64K
Aug 19, 2026$1.25$1.46$1.25$1.38139.89K
Aug 18, 2026$1.32$1.34$1.25$1.27135.77K
Aug 17, 2026$1.58$1.58$1.33$1.36296.84K
Aug 14, 2026$1.50$1.63$1.50$1.59155.8K

Latest CLDI news

The latest Smart Investors Daily articles mentioning CLDI.

Stock researchCompany · Overview

CLDI research

Overview

Company profile and research snapshot.

Company profile

Calidi Biotherapeutics Inc is a clinical-stage immuno-oncology company with technology designed to arm the immune system to fight cancer. The Company's stem cell-based platforms utilize potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in a many oncology indications, including high-grade gliomas and solid tumors. Its products include CLD-101 for Recurrent HGG; CLD-201 for Solid Tumors, and CLD-400 for certain lung cancer and Metastatic Solid Tumors. In addition to its pipeline products, the Company's is also engaged in discovery research of CLD-301 (AAA) for tumor Indications.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$5.50
Implied upside
—
Analysts
—
CLDI recent ratings
DateFirmRatingTarget
Jun 27, 2024Ladenburg ThalmannBuy—
May 15, 2024BairdOutperform—
Mar 21, 2024HC Wainwright & Co.Buy—
Mar 21, 2024BairdOutperform—
Nov 22, 2023HC Wainwright & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 8, 2026

Calidi Biotherapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

SAN DIEGO, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic medicines, today announces that it will participate in the H.C. Wainwright 28th Annual Global Investment Conference. The conference is being held on September 14 – 16, 2026 at the Lotte New York Palace Hotel. Eric Poma, Ph.D., Chief Executive Officer of Calidi Biotherapeutics will hold one-on-one meetin

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By